[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Iriyama N, Horikoshi A, Hatta Y, Kobayashi Y, Sawada S, Takeuchi J: Localized, splenic, diffuse large B-cell lymphoma presenting with hypersplenism: risk and benefit of splenectomy. Intern Med; 2010;49(11):1027-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized, splenic, diffuse large B-cell lymphoma presenting with hypersplenism: risk and benefit of splenectomy.
  • Herein we report a case of a localized, massive, diffuse large B-cell splenic lymphoma diagnosed by splenectomy.
  • Enhanced computed tomography scanning showed an irregularly enhanced effect in the spleen suggesting a diffuse splenic tumor.
  • After the operation, the patient recovered from the pancytopenia and pathology diagnosed diffuse large B-cell lymphoma.
  • Standard CHOP plus rituximab chemotherapy was given.
  • [MeSH-major] Hypersplenism / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Splenectomy / adverse effects. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519821.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Kim JK, Hahn JS, Kim GE, Yang WI: Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma. Yonsei Med J; 2005 Oct 31;46(5):703-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma.
  • Primary splenic lymphoma (PSL) is often defined as generalized lymphoma with splenic involvement as the dominant feature.
  • We investigated three cases of non-Hodgkin's splenic lymphoma that had different clinical features on presentation.
  • The patients' survival times from diagnosis ranged from 59 to 143 months, without evidence of relapse after splenectomy and chemotherapy, with or without radiotherapy.
  • Further studies are needed to evaluate the impact that different treatment modalities without splenectomy have on patient survival.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Splenic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Haematol. 2000 Mar;64(3):145-50 [10997879.001]
  • [Cites] Am J Clin Pathol. 1965 Apr;43:332-3 [14275850.001]
  • [Cites] Cancer. 1966 Apr;19(4):461-9 [5327041.001]
  • [Cites] Arch Intern Med. 1971 Feb;127(2):259-65 [5101153.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1606-19 [6548171.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2460-7 [6388805.001]
  • [Cites] Cancer. 1988 Oct 1;62(7):1433-8 [3416282.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2612-9 [2249201.001]
  • [Cites] Am J Hematol. 1991 Oct;38(2):95-100 [1951314.001]
  • [Cites] Surgery. 1992 Feb;111(2):224-7 [1736393.001]
  • [Cites] J Nucl Med. 1992 Jun;33(6):1183-5 [1597736.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):207-15 [8416717.001]
  • [Cites] Haematologica. 1994 May-Jun;79(3):286-93 [7926983.001]
  • [Cites] Yonsei Med J. 1997 Oct;38(5):270-84 [9409190.001]
  • [Cites] Clin Radiol. 1998 Feb;53(2):137-42 [9502091.001]
  • [Cites] Surg Gynecol Obstet. 1965 May;120:947-60 [14269844.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3731-3 [11054447.001]
  • (PMID = 16259071.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2810579
  •  go-up   go-down


3. Khan F, Vessal S, McKimm E, D'Souza R: Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma. BMJ Case Rep; 2010;2010
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma.
  • A gastrosplenic fistula is a rare complication of gastric and splenic lymphomas which can occur spontaneously or secondary to chemotherapy.
  • We report a case of a spontaneous gastrosplenic fistula secondary to a diffuse splenic large B cell lymphoma in a previously well 43-year-old patient.
  • CT imaging demonstrated the fistula, which was subsequently managed with chemotherapy.
  • [MeSH-major] Fistula / etiology. Fistula / radiography. Gastric Fistula / etiology. Gastric Fistula / radiography. Image Interpretation, Computer-Assisted. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / radiography. Multidetector Computed Tomography. Splenic Diseases / etiology. Splenic Diseases / radiography. Splenic Neoplasms / complications. Splenic Neoplasms / radiography
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cooperative Behavior. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interdisciplinary Communication. Methotrexate / administration & dosage. Patient Care Team. Radiographic Image Enhancement. Rituximab. Spleen / pathology. Spleen / radiography. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Fistulas.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 2002 Aug;95(8):941-2 [12190240.001]
  • [Cites] Asian J Surg. 2006 Oct;29(4):287-90 [17098664.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):994-6 [6349784.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2460-7 [6388805.001]
  • [Cites] Saudi Med J. 2007 Dec;28(12):1898-900 [18060225.001]
  • [Cites] Ann Hematol. 2008 Apr;87(4):337-8 [17929016.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):69-70 [18386245.001]
  • [Cites] Rev Esp Enferm Dig. 2009 Jan;101(1):76-8 [19335040.001]
  • [Cites] Rev Esp Enferm Dig. 2009 Mar;101(3):222-3 [19388805.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):e15-7 [19433680.001]
  • [Cites] Abdom Imaging. 2002 Nov-Dec;27(6):728-30 [12395264.001]
  • [Cites] Dis Colon Rectum. 1986 Aug;29(8):521-3 [3755392.001]
  • [Cites] Mayo Clin Proc. 1989 Jul;64(7):776-9 [2770360.001]
  • [Cites] Comput Med Imaging Graph. 1990 Jul-Aug;14(4):273-6 [2383867.001]
  • [Cites] J Clin Gastroenterol. 1991 Aug;13(4):478-81 [1918860.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):587-9 [8674934.001]
  • [Cites] J Thorac Imaging. 1996 Spring;11(2):150-2 [8820024.001]
  • [Cites] Am Surg. 1997 Nov;63(11):1007-10 [9358792.001]
  • [Cites] Gulf J Oncolog. 2008 Jan;(3):64-7 [20084800.001]
  • (PMID = 22791483.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  • [Other-IDs] NLM/ PMC3029570
  •  go-up   go-down


Advertisement
4. Singh A, Thapar V, Prabhu R, Naresh K, Joshi A, Supe A: Isolated splenic lymphoma: an elusive preoperative diagnosis. Indian J Gastroenterol; 2000 Oct-Dec;19(4):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic lymphoma: an elusive preoperative diagnosis.
  • Four patients underwent splenectomy for various clinical and radiological diagnoses and were found to have primary splenic lymphoma at surgery and histology.
  • The diagnosis was classical Hodgkin's lymphoma, mixed cellularity type (one case); marginal zone B-cell non-Hodgkin's lymphoma (one case); and large B cell type non-Hodgkin's lymphoma (two cases).
  • The first two patients had multiple nodules in the spleen measuring 0.1-0.5 cm while large cell lymphomas had large nodules (largest measuring 11 cm x 7 cm x 4 cm).
  • Mean follow up of these patients was 11 months; all patients received chemotherapy.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / surgery. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Splenic Diseases / diagnosis. Splenic Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Preoperative Care. Splenectomy / methods. Splenectomy / mortality. Splenomegaly / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059187.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


5. Takaku T, Miyazawa K, Sashida G, Shoji N, Shimamoto T, Yamaguchi N, Ito Y, Nakamura S, Mukai K, Ohyashiki K: Hepatosplenic alphabeta T-cell lymphoma with myelodysplastic syndrome. Int J Hematol; 2005 Aug;82(2):143-7
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic alphabeta T-cell lymphoma with myelodysplastic syndrome.
  • We describe a patient with hepatosplenic 33 T-cell lymphoma who showed pancytopenia and myelodysplasia.
  • This treatment resulted in a transient improvement of the cytopenia and a reduction of spleen size.
  • The pathologic findings for the spleen showed diffuse and disseminated infiltration of medium- to large-sized T-lymphocytes in the splenic red pulp.
  • These cells were immunohistochemically positive for CD3, CD5, CD7, CD8, CD16, CD56,T-cell receptor 33 (TCR33),T-cell intracellular antigen 1, and granzyme B but were negative for CD4, CD30, CD57, and TCR33.
  • These data suggested a diagnosis of hepatosplenic 33 T-cell lymphoma.
  • The patient received 8 courses of combination chemotherapy and achieved a partial remission; however, the dysplastic features of the marrow cells persisted after the partial remission was obtained.
  • Additional treatment with allogeneic bone marrow transplantation resulted in a transient complete remission; however, the patient relapsed 11 months later.
  • Because he had experienced no lymphadenopathy and showed dysplastic features in the bone marrow, the diagnosis was highly dependent on the pathologic findings for the resected spleen.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma, T-Cell / pathology. Myelodysplastic Syndromes / pathology. Receptors, Antigen, T-Cell, alpha-beta. Splenic Neoplasms / pathology

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Dec 15;102(13):4261-9 [12907441.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2612-9 [2249201.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Leukemia. 2000 Jun;14(6):991-7 [10865963.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):285-96 [11224598.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):459-63 [10716161.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4265-74 [8943863.001]
  • [Cites] Am J Pathol. 1990 Sep;137(3):617-28 [1698028.001]
  • [Cites] Am J Hematol. 2001 Jan;66(1):49-52 [11426493.001]
  • [Cites] Blood. 1990 Jun 1;75(11):2213-9 [2140703.001]
  • [Cites] Intern Med. 2000 Jul;39(7):570-5 [10888214.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e119-22 [12653597.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):1027-32 [10895827.001]
  • (PMID = 16146847.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


6. Vaidyanathan S, Soni BM, Hughes PL, O'Brien D, Oo T, Aung W: Glandular fever and pulmonary artery thrombosis in a paraplegic patient, who had undergone splenectomy for splenic trauma sustained along with spinal cord injury: misdiagnosed initially as urine infection and later as lymphoma when CT scan revealed enlarged lymph nodes: a case report. Cases J; 2009;2(1):76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glandular fever and pulmonary artery thrombosis in a paraplegic patient, who had undergone splenectomy for splenic trauma sustained along with spinal cord injury: misdiagnosed initially as urine infection and later as lymphoma when CT scan revealed enlarged lymph nodes: a case report.
  • BACKGROUND: A 36-year-old male sustained fracture of first lumbar vertebra, splenic tear and paraplegia in a motorcycle accident in 2001; splenectomy was performed.
  • With a diagnosis of urine infection, he was prescribed ciprofloxacin, followed by trimethoprim, amoxicillin, and gentamicin, as temperature did not subside.
  • White cell count was 21.2 x 109/L; lymphocytes were 13.05 x 109/L (1.00 - 4.00).
  • Therefore, computerised tomography (CT) of chest and abdomen was performed.
  • Radiological diagnosis was lymphoma.
  • Cell marker showed an excess of large granular lymphocytes and activated lymphocytes.
  • (1) Although routine administration of antibiotic to a spinal cord injury patient with pyrexia may be acceptable in outpatient setting, other possibilities such as infection by multi-drug resistant organism, viral infection, venous or, arterial thrombosis should be considered if a patient does not respond promptly to antibacterial therapy. (2) When full blood count showed lymphocytosis (comprising > 50% of white blood cells) with atypical morphology, lymphocyte surface markers, Paul Bunnell test, and Epstein Barr virus serology should be performed.
  • These tests would have led to a diagnosis of infectious mononucleosis, and abdominal imaging studies could have been avoided. (3) Lymphoid hyperplasia is the hallmark of infectious mononucleosis; therefore, we should have suspected glandular fever rather than lymphoma when CT scan revealed enlarged lymph nodes in abdomen, mediastinum, axillae and inguinal regions in this patient, who had lymphocytosis with atypical morphology. (4) A soft tissue mass, situated inferior to left hemidiaphragm in this asplenic patient, was misinterpreted as lymph nodes; review of CT led to the correct diagnosis of splenunculus. (5) Acute infection with Epstein Barr virus may lead to transient induction of anti-phospholipid antibodies, which can cause vascular thrombosis. (6) This case illustrates the value of reviewing test results and discussion with senior doctors, as these measures help to recognize medical errors and improve patient care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1948 Aug;3(8):830-57 [18873529.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2068 [18083406.001]
  • [Cites] J Clin Virol. 2005 Mar;32(3):245-7 [15722031.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):478-80 [12683879.001]
  • [Cites] Arch Pathol Lab Med. 1999 Oct;123(10):875-81 [10506437.001]
  • [Cites] Spinal Cord. 1998 Dec;36(12):838-46 [9881733.001]
  • [Cites] J Spinal Cord Med. 2003 Fall;26(3):248-53 [14997967.001]
  • [Cites] Arch Phys Med Rehabil. 2004 Nov;85(11):1757-63 [15520970.001]
  • (PMID = 19161590.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2635124
  •  go-up   go-down


7. Biswas S, Keddington J, McClanathan J: Large B-cell lymphoma presenting as acute abdominal pain and spontaneous splenic rupture; a case report and review of relevant literature. World J Emerg Surg; 2006;1:35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B-cell lymphoma presenting as acute abdominal pain and spontaneous splenic rupture; a case report and review of relevant literature.
  • BACKGROUND: Spontaneous rupture of the spleen is an uncommon dramatic abdominal emergency that requires immediate diagnosis and prompt surgical treatment to ensure the patients survival.
  • Infections have been cited in most cases involving splenic rupture but are rare in hematological malignancies despite frequent involvement of the spleen.
  • METHODS AND MATERIALS: We present a case of a splenic rupture caused by infiltration of B-cell lymphoma.
  • The patient underwent a splenectomy after initial resuscitation and the operative finding was that of a massively enlarged spleen with areas of tumor extruding through the splenic capsule.
  • RESULT AND CONCLUSION: Although the spleen is often involved in hematological malignancies, splenic rupture is an infrequent occurrence.
  • In a recent literature review 136 cases were of splenic rupture secondary to hematological malignancy were identified.
  • Acute leukemia and non Hodgkin lymphoma were the frequent causes followed by chronic myelogenous leukemia.
  • Male sex, adulthood, severe splenomegaly and cytoreductive chemotherapy were factors more often associated with splenic rupture.
  • Emergency splenectomy remains the cornerstone treatment for splenic rupture.
  • We present a case report of a "spontaneous splenic rupture" and discuss the presentation, etiology and treatment options along with discussion of relevant literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 May;83(5):632 [8689204.001]
  • [Cites] Pathology. 1994 Oct;26(4):493-6 [7892057.001]
  • [Cites] AJR Am J Roentgenol. 1995 Mar;164(3):631-5 [7863884.001]
  • [Cites] Cancer. 1981 Dec 15;48(12):2729-33 [7306928.001]
  • [Cites] Am J Clin Pathol. 1984 Jul;82(1):104-9 [6234792.001]
  • [Cites] Mich Med. 1966 Feb;65(2):105-10 [5901949.001]
  • [Cites] Arch Surg. 1972 May;104(5):652-7 [4503094.001]
  • [Cites] Am J Emerg Med. 1989 Jan;7(1):28-31 [2643958.001]
  • [Cites] Acta Haematol. 2005;113(4):255-7 [15983432.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):131-5 [14508801.001]
  • [Cites] Int Abstr Surg. 1958 Jan;106(1):1-11 [13495867.001]
  • [Cites] Lupus. 2001;10(12):876-8 [11787878.001]
  • [Cites] J Pediatr Surg. 1999 Mar;34(3):498-9 [10211667.001]
  • [Cites] Eur J Surg. 1999 Jul;165(7):712-3 [10452269.001]
  • [Cites] Ann Hematol. 2000 Mar;79(3):158-60 [10803939.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):3-8 [11298158.001]
  • [Cites] Clin Infect Dis. 1993 Feb;16(2):223-32 [8443301.001]
  • [Cites] Radiographics. 1994 Mar;14(2):307-32 [8190956.001]
  • [Cites] Ann Hematol. 1996 Dec;73(6):297-302 [9003161.001]
  • [Cites] Clin Infect Dis. 1997 Aug;25(2):336-7 [9332543.001]
  • [Cites] Semin Arthritis Rheum. 1997 Dec;27(3):141-55 [9431585.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):276-8 [9934775.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):89-93 [9022775.001]
  • (PMID = 17129392.001).
  • [ISSN] 1749-7922
  • [Journal-full-title] World journal of emergency surgery : WJES
  • [ISO-abbreviation] World J Emerg Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1712221
  •  go-up   go-down


8. Szotkowski T, Szotkowska R, Pikalova Z, Tichy T, Flodr P, Tichy M, Houserkova D, Benysek V, Zlamalova N, Ruzicka V, Indrak K: Spontaneous splenic rupture in two patients with hematologic malignancy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun;151(1):113-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous splenic rupture in two patients with hematologic malignancy.
  • BACKGROUND: Spontaneous splenic rupture (SSR) is a very rare complication described in several hundred patients, mainly as case reports.
  • It is defined as a splenic rupture without antecedent injury.
  • PATIENTS: The first patient was admitted to hospital because of planned chemotherapy for relapsed hairy cell leukemia.
  • The diagnose of hematologic malignancy (diffuse large B-cell lymphoma) was determined subsequently on the basis of histological examination of the spleen.
  • CONCLUSION: It is necessary to consider SSR not only in patients with known diagnosis of malignant disease but in the patients with negative anamnesis, too.
  • [MeSH-major] Leukemia, Hairy Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Splenic Rupture / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690752.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


9. Kanai Y, Matsuda M, Iwanaga T, Hashimoto S, Maeda Y, Kanamaru A, Itagaki N: [Diffuse large B-cell lymphoma presenting with hypoglossal nerve palsy and great occipital neuralgia]. Rinsho Ketsueki; 2009 Feb;50(2):113-5
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse large B-cell lymphoma presenting with hypoglossal nerve palsy and great occipital neuralgia].
  • Soluble IL-2 receptor was elevated and malignant lymphoma was clinically diagnosed.
  • After radiation therapy to the lesion on the petrous bone, splenectomy was performed.
  • Pathological findings established a diagnosis of diffuse large B-cell lymphoma.
  • After chemotherapy consisting of rituximab and THP-COP, complete remission was achieved.
  • [MeSH-major] Hypoglossal Nerve Diseases / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Neoplasms, Multiple Primary. Neuralgia / etiology. Occipital Bone / innervation. Petrous Bone. Skull Neoplasms / complications
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Combined Modality Therapy. Humans. Male. Receptors, Interleukin-2 / blood. Remission Induction. Splenic Neoplasms / complications. Splenic Neoplasms / diagnosis. Splenic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265306.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-2
  •  go-up   go-down


10. Ou J, Yang L, Ren L, Tang X, Li T, Wu S: [The clinical features and tumor cells characteristics of splenic marginal zone lymphoma]. Zhonghua Nei Ke Za Zhi; 2002 Jan;41(1):28-30
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical features and tumor cells characteristics of splenic marginal zone lymphoma].
  • OBJECTIVE: To deepen the understanding of splenic marginal zone lymphoma (SMZL) and improve the level of diagnosis and therapy.
  • RESULTS: The spleen was large with uniform parenchyma and smooth surface.
  • Lymph nodes in the splenic hilum were infiltrated by tumor cells.
  • After splenectomy, COP chemotherapy and IFNalpha-2a were given and the abnormally increased lymphocytes decreased to normal level.
  • Presence of monoclonal rearranged IgH gene is in favor of the diagnosis.
  • [MeSH-major] Germinal Center / pathology. Lymphoma, B-Cell / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antigens, CD20 / biosynthesis. Antigens, CD45 / biosynthesis. Cyclophosphamide / therapeutic use. Female. Gene Rearrangement. HLA-DR Antigens / biosynthesis. Humans. Immunoglobulin Heavy Chains / genetics. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Splenectomy. Splenomegaly / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11940293.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / HLA-DR Antigens; 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins c-bcl-2; 8N3DW7272P / Cyclophosphamide; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


11. Audouin J, Le Tourneau A, Molina T, Camilleri-Broët S, Adida C, Comperat E, Benattar L, Delmer A, Devidas A, Rio B, Diebold J: Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol; 2003 Aug;122(3):404-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes.
  • We studied 86 bone marrow biopsies (BMB) from 58 patients presenting with primary splenic marginal zone lymphoma (PSMZL).
  • In 42 patients, a splenectomy was performed which enabled a histopathological diagnosis.
  • In 16 recently observed patients, 17 BMB led to PSMZL diagnosis, and these patients were treated without splenectomy.
  • Seven different patterns of infiltrates were recognized: intravascular, interstitial, nodular, massive, plasmacytic mimicking myeloma and transformation into large B-cell lymphoma (DLBCL).
  • The association of an intravascular infiltrate and nodules with a germinal centre and/or a marginal zone favoured a diagnosis of MZL.
  • Immunohistochemistry demonstrated the expression of B cell-associated antigens and, in 40% of the patients, a monotypic lymphoplasmacytic cell component.
  • In the past, such cases have been diagnosed as lymphoplasmacytic lymphoma.
  • Successive biopsies showed progression and, after chemotherapy, a slight decrease in infiltrates.
  • The patterns described are not specific for PSMZL and occur also in primary nodal MZL and, more rarely, in MALT-type lymphoma.
  • [MeSH-major] B-Lymphocytes / pathology. Bone Marrow Cells / pathology. Leukemic Infiltration. Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Examination. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Plasma Cells / pathology. Splenectomy. Waldenstrom Macroglobulinemia / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2004 Jan;124(2):252-3 [14687039.001]
  • (PMID = 12877667.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Anup N, Dalus D, Suresh MK, Nileena N: Splenic tumor presenting as pyrexia of unknown origin. J Assoc Physicians India; 2007 Nov;55:805-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic tumor presenting as pyrexia of unknown origin.
  • Here we present a case of a splenic tumor, which after histopathology and immunohistochemistry, two possibilities were considered, a diffuse large cell lymphoma--plasmablastic variant and second an anaplastic plasmacytoma.
  • The patient was treated with chemotherapy and on followup he has no evidence of recurrence or any residual lesion.
  • [MeSH-major] Fever of Unknown Origin / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Plasmacytoma / diagnosis. Splenic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290559.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


13. Cho SG, Koh YB, Chang HS, Park G, Kang CS, Park JW, Min WS: Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation. Eur J Haematol; 2005 Mar;74(3):259-62
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation.
  • A 25-yr-old man had been diagnosed as having CD30(+) anaplastic large cell lymphoma associated with hemophagocytic syndrome (HS).
  • He received aggressive frontline chemotherapies and consolidation with autologous peripheral blood stem cell transplantation (PBSCT) following high-dose chemotherapy combined with splenic irradiation (720 cGy in fraction of 180 cGy).
  • However, HS recurred on day 50 of PBSCT without radiologic evidence of lymphoma relapse.
  • HS was completely resolved and he has been alive well and in complete remission (CR), 60 months after initial diagnosis.
  • [MeSH-major] Histiocytosis, Non-Langerhans-Cell / therapy. Interferon-alpha / therapeutic use. Lymphoma, Large-Cell, Anaplastic / complications. Splenectomy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Humans. Male. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction / methods

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693797.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


14. Sissolak G, Juritz J, Sissolak D, Wood L, Jacobs P: Lymphoma--emerging realities in sub-Saharan Africa. Transfus Apher Sci; 2010 Apr;42(2):141-50
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma--emerging realities in sub-Saharan Africa.
  • Substantial geographical differences exist for Hodgkin and other lymphoproliferative disorders with these having previously been documented in a report from the lymphoma reclassification project.
  • Median age was 55.2 years 61% were males, 10% had Hodgkin lymphoma and, overall, constitutional symptoms were present in 20%.
  • Prior to referral 19% had received chemotherapy and a further 20% some form of irradiation.
  • Median survival in hairy cell leukaemia (n=14), chronic lymphocytic leukaemia-small lymphocytic lymphoma (n=103), Hodgkin (n=41) and follicular lymphoma (n=59) was not reached at the time of analysis and exceeded 36 months.
  • This was followed by 32 months for those with mantle cell (n=7), splenic (n=2) and extranodal marginal cell (n=11), 24 months for T-cell lymphomas (n=24), 20 months for diffuse large B-cell variants (n=88) but only 12 months for the aggressive tumours exemplified by Burkitt (n=7) and lymphoblastic subtypes (n=6).
  • Adverse factors were constitutional symptoms, prior treatment with chemotherapy, intermediate or high-risk scores as defined by the international prognostic index, histologic grading and certain anatomical sites of primary tumour.
  • In contrast gender, staging by Rye or Rai classification, retroviral infection and prior treatment with radiotherapy were without effect.
  • Overall survival at 3 years in each category was compared to the curve for the entire cohort and was 100% in hairy cell leukaemia receiving two chlorodeoxyadenosine and greater than 88% in Hodgkin lymphoma treated according to the German study group protocols (p=0.0004).
  • Corresponding figures for chronic lymphocytic leukaemia-small lymphocytic lymphoma were 82% (p=0.0006), follicular lymphoma 71% (p=0.060), peripheral T-cell lymphoma 43% (p=0.0156), diffuse large B-cell lymphoma 39% (p<0.0001), aggressive tumours 25% (p=0.0002) and for the indolent categories including mantle cell, splenic and extra nodal marginal cell lymphomas 22% (p=0.2023).
  • Outcome argues in favour of patient management by a multidisciplinary team implicit in which are standardised protocols for diagnosis, staging and treatment.
  • [MeSH-major] Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Ltd.
  • (PMID = 20149748.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


15. Foti R, Fazio P, Lizzio G, Leonardi R: [Angioedema: first manifestation of non-Hodgkin's lymphoma]. Ann Ital Med Int; 2002 Jul-Sep;17(3):185-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioedema: first manifestation of non-Hodgkin's lymphoma].
  • In a 48-year-old male patient a diagnosis of a non-Hodgkin lymphoma was made after two episodes of angioedema.
  • Abdominal ultrasonography and computed tomography showed two solid splenic masses infiltrating the greater curvature of the stomach and a 2 cm aortic lymph node.
  • A diagnosis of anaplastic large-cells lymphoma CD30+, anaplastic lymphoma kinase negative was made.
  • The disappearance of the neoplastic gastric infiltration and the decrease in size of the aortic lymph node and splenic mass were achieved after chemotherapy.
  • [MeSH-major] Angioedema / etiology. Autoimmune Diseases / etiology. Complement C1 Inactivator Proteins / deficiency. Complement C1 Inactivator Proteins / immunology. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / immunology. Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Proteins / analysis. Prednisone / administration & dosage. Spleen / pathology. Stomach / pathology. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Ital Med Int. 2002 Jul-Sep;17(3):143-5 [12402660.001]
  • (PMID = 12402667.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Complement C1 Inactivator Proteins; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


16. Niitsu N, Kohri M, Togano T, Nakamine H, Nakamura S, Iwabuchi K, Higashihara M: Development of hepatosplenic gammadelta T-cell lymphoma with pancytopenia during early pregnancy: a case report and review of the literature. Eur J Haematol; 2004 Nov;73(5):367-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of hepatosplenic gammadelta T-cell lymphoma with pancytopenia during early pregnancy: a case report and review of the literature.
  • Lymphomas rarely develop during pregnancy, but hepatosplenic gammadelta T-cell lymphoma (HSgammadeltaTCL) is extremely rare.
  • We encountered a case of T-cell intracellular antigen-1 (TIA-1) positive and granzyme B-positive HSgammadeltaTCL that developed early during the course of pregnancy.
  • The patient was a 31-yr-old female who was referred to our hospital because of pancytopenia and splenomegaly at the time of the14th week of her gestation.
  • Histopathological examination of the spleen, which was resected 28 d after delivery for a diagnostic purpose, revealed medium to large-sized nodules composed of dense proliferation of lymphoid cells having round to oval-shaped nuclei and abundant weakly eosinophilic cytoplasm.
  • They were CD3epsilon+, mCD3+, CD4-, CD8-, CD56+, CD79a-, T-cell receptor (TCR)-gammadelta protein+, TIA-1+, and granzyme B+ by either immunohistochemistry or flow cytometry.
  • Thus, the patient was diagnosed as having HSgammadeltaTCL, and combination chemotherapy was initiated.
  • To our knowledge, this is the first case report of HSgammadeltaTCL that developed during pregnancy.
  • Pathogenesis of pregnancy-associated lymphoma is not known, but it is possible that maternal immunity during pregnancy or a hormonal imbalance, such as a change in the progesterone level, induces the development of lymphoma.
  • Pregnancy-associated lymphoma is resistant to standard chemotherapy and is associated with poor prognosis.
  • Therefore, it is important to accumulate clinicopathologic data of such cases for the development of a treatment modality.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis. Pancytopenia. Pregnancy Complications, Neoplastic. Receptors, Antigen, T-Cell, gamma-delta / analysis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cesarean Section. Female. Gestational Age. Humans. Immunohistochemistry. Immunophenotyping. Pregnancy. Remission Induction. Spleen / chemistry. Spleen / pathology. Spleen / surgery. Splenectomy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15458516.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Number-of-references] 14
  •  go-up   go-down


17. Ferreri AJ, Dognini GP, Campo E, Willemze R, Seymour JF, Bairey O, Martelli M, De Renz AO, Doglioni C, Montalbán C, Tedeschi A, Pavlovsky A, Morgan S, Uziel L, Ferracci M, Ascani S, Gianelli U, Patriarca C, Facchetti F, Dalla Libera A, Pertoldi B, Horváth B, Szomor A, Zucca E, Cavalli F, Ponzoni M, International Extranodal Lymphoma Study Group (IELSG): Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica; 2007 Apr;92(4):486-92
Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions.
  • BACKGROUND AND OBJECTIVES: This study explored variations in the clinical manifestations of intravascular lymphoma (IVL) on the bases of the association with hemophagocytosis and the country where the diagnosis was made.
  • Conversely, Japanese and non-Japanese patients with hemophagocytosis-related IVL more frequently had stage IV disease, fever, hepato-splenic involvement, marrow infiltration, dyspnea, anemia, and thrombocytopenia, and rarely exhibited cutaneous or central nervous system involvement.
  • In Western patients, anthracycline-based chemotherapy was associated with a 52% remission rate, and a 2-year overall survival of 46%.
  • INTERPRETATION AND CONCLUSIONS: The clinical features of IVL vary according to the association with hemophagocytosis, regardless of the country in which the diagnosis is made.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Vascular Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asia / epidemiology. Asian Continental Ancestry Group / statistics & numerical data. Brain Neoplasms / epidemiology. Brain Neoplasms / ethnology. Brain Neoplasms / pathology. Disease Progression. Europe / epidemiology. European Continental Ancestry Group / statistics & numerical data. Female. Follow-Up Studies. Forecasting. Humans. Japan / ethnology. Male. Middle Aged. Organ Specificity. Phenotype. Prognosis. Retrospective Studies. Skin Neoplasms / epidemiology. Skin Neoplasms / ethnology. Skin Neoplasms / pathology. Surveys and Questionnaires. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2007 Apr;92(4):434-6 [17488652.001]
  • (PMID = 17488659.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


18. Ruiz-Hernández G, Scaglione C, Delgado-Bolton RC, Gutiérrez-García A, Madero L, Jiménez-Vicioso A, Carreras-Delgado JL: [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF]. Rev Esp Med Nucl; 2004 Mar-Apr;23(2):124-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF].
  • Biopsy of the mediastinal mass revealed the presence of diffuse large B-cell non-Hodgkin's lymphoma.
  • Treatment included 4 cycles of chemotherapy followed by 7 days of subcutaneous granulocyte colony-stimulating factor (G-CSF, Lenogastrim) at a dose of 5 mg/Kg/day.
  • Following treatment, a CT scan was performed to evaluate response, finding a calcification of the mass without significant reduction of the overall size.
  • Because CT was inconclusive in the assessment of response to therapy, a 18F-FDG PET scan was performed.
  • The 18F-FDG PET scan did not show any pathological uptake in the mediastinum but revealed a splenic and bone marrow diffusely increased 18F-FDG uptake.
  • The differential diagnosis included a secondary effect induced by G-CSF therapy as one of the main possibilities, but other possibilities such as a malignant infiltration by lymphoma could not be discarded.
  • Thus, the benign and reactive nature of the splenic and bone marrow 18F-FDG increased uptake found in the previous study was confirmed.
  • We consider that the stimulating effect that G-CSF therapy has on the spleen and bone marrow must be taken into account when performing a 18F-FDG PET scan, as it can be an important source of false-positive results.
  • [MeSH-major] Bone Marrow / metabolism. Bone Marrow / radionuclide imaging. Fluorodeoxyglucose F18 / metabolism. Granulocyte Colony-Stimulating Factor / adverse effects. Radiopharmaceuticals / metabolism. Spleen / metabolism. Spleen / radionuclide imaging. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15000944.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


19. Wu H, Wasik MA, Przybylski G, Finan J, Haynes B, Moore H, Leonard DG, Montone KT, Naji A, Nowell PC, Kamoun M, Tomaszewski JE, Salhany KE: Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Clin Pathol; 2000 Apr;113(4):487-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients.
  • We report 2 cases of renal transplant recipients in whom hepatosplenic gamma-delta T-cell lymphoma (gamma-delta HSTCL) developed 5 and 10 years after transplantation.
  • Markedly atypical lymphoid infiltrate of intermediate to large cells was observed in the spleen, liver, and bone marrow.
  • The malignant cells showed typical immunophenotype of gamma-delta T cells (CD2+, CD3+, CD4-, CD8-, CD7+, gamma-delta T-cell receptor-positive, and alpha-beta T-cell receptor-negative) with clonal T-cell receptor gene rearrangement and were of the V-delta-1 subset.
  • In addition, the cells contained a cytolytic granule-associated protein, TIA-1, and Fas ligand, indicating cytotoxic T-cell differentiation.
  • The malignant T cells in both cases were of host tissue origin.
  • Despite initial response to chemotherapy, both patients died within 6 months of diagnosis.
  • [MeSH-major] Kidney Transplantation / adverse effects. Liver Neoplasms / etiology. Lymphoma, T-Cell / etiology. Proteins. Receptors, Antigen, T-Cell, gamma-delta / immunology. Splenic Neoplasms / etiology
  • [MeSH-minor] Adult. DNA, Neoplasm / analysis. Fas Ligand Protein. Fatal Outcome. Female. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Membrane Glycoproteins / metabolism. Membrane Proteins / metabolism. Middle Aged. Poly(A)-Binding Proteins. Polymerase Chain Reaction. RNA-Binding Proteins / metabolism. Receptors, Interleukin-2 / blood

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761449.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Poly(A)-Binding Proteins; 0 / Proteins; 0 / RNA-Binding Proteins; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Interleukin-2; 0 / TIA1 protein, human
  •  go-up   go-down


20. Macon WR, Levy NB, Kurtin PJ, Salhany KE, Elkhalifa MY, Casey TT, Craig FE, Vnencak-Jones CL, Gulley ML, Park JP, Cousar JB: Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol; 2001 Mar;25(3):285-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas.
  • Hepatosplenic gammadelta T-cell lymphoma is a distinct entity, characterized by occurrence in young adult males with hepatosplenomegaly, B-symptoms, peripheral blood cytopenias, and no lymphadenopathy; lymphomatous infiltrates in the splenic red pulp, hepatic sinusoids, and bone marrow sinuses; T-cell receptor (TCR) gammadelta chains and a cytotoxic T-cell phenotype; isochromosome 7q; and an aggressive clinical course.
  • In comparison, this study describes the clinicopathologic features of 14 hepatosplenic T-cell lymphomas expressing TCR alphabeta chains.
  • Clinical presentation was similar to that described previously for hepatosplenic gammadelta T-cell lymphomas, except for the female preponderance and age distribution (5 patients younger than 13 years of age and 5 patients older than 50 years of age).
  • Disease distribution was primarily in the splenic red pulp and hepatic sinusoids, although liver infiltrates were largely periportal in four cases.
  • Four lymphomas contained primarily large cells with irregular nuclei, dispersed chromatin, discernible nucleoli, and moderate to abundant cytoplasm.
  • Tumor cells in all 14 lymphomas were cytotoxic alphabeta T-cells; 13 co-expressed natural killer cell-associated antigens and showed T-cell clonality.
  • Eleven patients are dead, eight within a year of diagnosis, and two patients have maintained complete remissions after combination chemotherapy.
  • These data show that hepatosplenic T-cell lymphomas include an alphabeta-subtype.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma, T-Cell / pathology. Receptors, Antigen, T-Cell, alpha-beta / metabolism. Receptors, Antigen, T-Cell, gamma-delta / metabolism. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / pathology. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Infant. Infant, Newborn. Karyotyping. Lymph Nodes / pathology. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11224598.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


21. Chandra P, Wen YH, Tuli S, Raphael BG, Amorosi EL, Medeiros LJ, Ibrahim S: Postchemotherapy histiocyte-rich pseudotumor involving the spleen. Am J Clin Pathol; 2009 Sep;132(3):342-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report 2 cases of splenic postchemotherapy histiocyte-rich pseudotumor.
  • Each patient had a history of diffuse large B-cell lymphoma, treated with multiagent chemotherapy.
  • Computed tomography scans performed on both patients showed splenic masses.
  • A positron emission tomography scan performed on 1 patient showed increased metabolic activity.
  • The preoperative diagnosis in both patients was recurrent lymphoma, prompting splenectomy.
  • The splenectomy specimens showed multiple, tan-white, firm nodules, up to 3.5 cm in diameter, that were histologically composed of central necrotic B cells (CD20+/CD3-), consistent with necrotic lymphoma, surrounded by numerous lipid-laden (xanthomatous) histiocytes.
  • Clinical staging studies at the time of splenectomy showed no other sites of disease.
  • We conclude that these histologic and immunophenotypic findings represent chemotherapy-induced tumor necrosis with a florid histiocytic reaction mimicking residual viable lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Histiocytosis / etiology. Histiocytosis / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Spleen / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687310.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Rothermel LD, Chadwick CL, Thambi-Pillai T: Gastrosplenic fistula: etiologies, diagnostic studies, and surgical management. Int Surg; 2010 Jul-Sep;95(3):270-2
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reported causes include a spontaneous malignant fistula, chemotherapy for gastric or splenic malignancies, peptic ulcer disease, Crohn disease, and trauma.
  • We report a case of a gastrosplenic fistula discovered on abdominal computed tomography with contrast, performed in a patient with a history suspicious for malignancy.
  • It was at that time that the diagnosis of a large B-cell lymphoma was made.
  • Postoperative chemotherapy was initiated and led to remission of the malignancy.
  • Though most cases require definitive surgical repair, the treatment plans for gastrosplenic fistulas depend largely on the etiology of the lesion.
  • [MeSH-major] Gastric Fistula / etiology. Lymphoma, B-Cell / complications. Splenic Diseases / etiology. Splenic Neoplasms / complications
  • [MeSH-minor] Aged. Blood Loss, Surgical. Chemotherapy, Adjuvant. Humans. Male. Remission Induction. Splenectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067009.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Carr JA, Shurafa M, Velanovich V: Surgical indications in idiopathic splenomegaly. Arch Surg; 2002 Jan;137(1):64-8
Genetic Alliance. consumer health - Splenomegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: The incidence of primary lymphoma of the spleen in patients with idiopathic splenomegaly is significant.
  • SETTING: A large tertiary care hospital.
  • Of these, 18 had idiopathic splenomegaly despite prior workup with computed tomography, peripheral smear, bone marrow biopsy, and laboratory testing.
  • INTERVENTION: All 18 patients underwent open splenectomy for diagnosis and treatment of their cytopenias.
  • MAIN OUTCOME MEASURE: Incidence of lymphoma in the pathologic specimens.
  • In all 18 patients, the surgical specimen provided a diagnosis.
  • Six patients with the benign diagnosis of hypersplenism received no further interventions, and the cytopenias resolved in all 6 cases.
  • The 7 remaining patients (39%) were diagnosed with lymphoma.
  • Five had marginal zone lymphoma, and 2 had a more aggressive B-cell lymphoma.
  • Three patients required chemotherapy, but 4 are still in remission since their splenectomies and show no evidence of active disease.
  • CONCLUSIONS: A high percentage of patients with splenomegaly of unknown etiology will have primary lymphoma of the spleen.
  • Splenectomy is both diagnostic and therapeutic and should be considered for all patients with idiopathic splenomegaly.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Splenic Neoplasms / epidemiology. Splenomegaly / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11772218.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Cines DB, Liebman H, Stasi R: Pathobiology of secondary immune thrombocytopenia. Semin Hematol; 2009 Jan;46(1 Suppl 2):S2-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary immune thrombocytopenic purpura (ITP) remains a diagnosis of exclusion both from nonimmune causes of thrombocytopenia and immune thrombocytopenia that develops in the context of other disorders (secondary immune thrombocytopenia).
  • The pathobiology, natural history, and response to therapy of the diverse causes of secondary ITP differ from each other and from primary ITP, so accurate diagnosis is essential.
  • Immune thrombocytopenia can be secondary to medications or to a concurrent disease, such as an autoimmune condition (eg, systemic lupus erythematosus [SLE], antiphospholipid antibody syndrome [APS], immune thyroid disease, or Evans syndrome), a lymphoproliferative disease (eg, chronic lymphocytic leukemia or large granular T-lymphocyte lymphocytic leukemia), or chronic infection, eg, with Helicobacter pylori, human immunodeficiency virus (HIV), or hepatitis C virus (HCV).
  • Response to infection may generate antibodies that cross-react with platelet antigens (HIV, H pylori) or immune complexes that bind to platelet Fcgamma receptors (HCV), and platelet production may be impaired by infection of megakaryocyte (MK) bone marrow-dependent progenitor cells (HCV and HIV), decreased production of thrombopoietin (TPO), and splenic sequestration of platelets secondary to portal hypertension (HCV).
  • Proper diagnosis and treatment of the underlying disorder, where necessary, play an important role in patient management.

  • Genetic Alliance. consumer health - Immune thrombocytopenia.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1975 Aug;64(2):180-91 [1171614.001]
  • [Cites] Arthritis Rheum. 1981 Aug;24(8):1024-36 [7284049.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):714-7 [6178333.001]
  • [Cites] Q J Med. 1991 Jul;80(291):605-12 [1946940.001]
  • [Cites] J Clin Invest. 1992 Feb;89(2):356-64 [1737832.001]
  • [Cites] Blood. 1992 Jul 1;80(1):162-9 [1611083.001]
  • [Cites] J Rheumatol. 1992 May;19(5):803-6 [1613714.001]
  • [Cites] N Engl J Med. 1992 Dec 17;327(25):1779-84 [1435932.001]
  • [Cites] Haematologica. 1992 Sep-Oct;77(5):398-401 [1483588.001]
  • [Cites] Acta Paediatr. 1993 Mar;82(3):267-70 [8495082.001]
  • [Cites] Lancet. 1993 Nov 20;342(8882):1274-5 [7694021.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2263-7 [7892259.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1719-26 [7535585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3234-8 [7536928.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1347-9 [7539157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5292-6 [7777500.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3444-51 [7780132.001]
  • [Cites] Cell. 1995 Jun 16;81(6):935-46 [7540117.001]
  • [Cites] FEBS Lett. 1995 Aug 14;370(1-2):63-8 [7544303.001]
  • [Cites] FEBS Lett. 1995 Dec 27;377(3):497-501 [8549784.001]
  • [Cites] Blood. 1996 May 15;87(10):4068-71 [8639762.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):704-6 [8652398.001]
  • [Cites] Pediatr Infect Dis J. 1996 Jan;15(1):88-90 [8684885.001]
  • [Cites] Clin Exp Rheumatol. 1995 Nov-Dec;13 Suppl 13:S39-43 [8730475.001]
  • [Cites] Blood. 1996 Jul 1;88(1):3-40 [8704187.001]
  • [Cites] Lancet. 1996 Sep 14;348(9029):719-23 [8806292.001]
  • [Cites] Blood. 2004 Jan 15;103(2):500-6 [12969975.001]
  • [Cites] Am J Med. 1996 Nov;101(5):502-7 [8948273.001]
  • [Cites] Blood. 1997 Jan 15;89(2):483-92 [9002950.001]
  • [Cites] Thromb Haemost. 1997 May;77(5):808-14 [9184382.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] J Hepatol. 1997 Jul;27(1):127-31 [9252085.001]
  • [Cites] Br J Haematol. 1997 Aug;98(2):336-41 [9266930.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1787-98 [9292511.001]
  • [Cites] Br J Haematol. 1997 Sep;98(4):873-9 [9326182.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1479-95 [9473211.001]
  • [Cites] Gut. 1998 Mar;42(3):338-43 [9577338.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):656-8 [9674737.001]
  • [Cites] Haematologica. 1998 Jul;83(7):669-70 [9718878.001]
  • [Cites] Scand J Infect Dis. 1998;30(2):115-8 [9730294.001]
  • [Cites] Clin Exp Immunol. 1998 Sep;113(3):373-8 [9737665.001]
  • [Cites] Lancet. 1998 Sep 12;352(9131):878 [9742983.001]
  • [Cites] Ann Intern Med. 1998 Dec 1;129(11):886-90 [9867731.001]
  • [Cites] Blood. 2003 Aug 1;102(3):887-95 [12676790.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1670-7 [12738668.001]
  • [Cites] Nat Med. 2003 Sep;9(9):1123-4 [12937414.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):91-6 [14675413.001]
  • [Cites] Blood. 2004 Feb 1;103(3):890-6 [12920031.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1364-9 [14576051.001]
  • [Cites] Arch Intern Med. 2004 Feb 23;164(4):361-9 [14980986.001]
  • [Cites] Ann Intern Med. 2004 May 4;140(9):766-7 [15126268.001]
  • [Cites] J Thromb Haemost. 2004 Jun;2(6):985-92 [15140135.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):434-40 [14963696.001]
  • [Cites] Indian J Pediatr. 2004 Jun;71(6):505-7 [15226559.001]
  • [Cites] J Clin Invest. 1966 May;45(5):645-57 [5327481.001]
  • [Cites] N Engl J Med. 1974 Jan 31;290(5):249-51 [4855568.001]
  • [Cites] N Engl J Med. 1974 May 2;290(18):989-93 [4594526.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2346-53 [16304054.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):230-9 [16616070.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):427-31 [16480433.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1212-8 [16380230.001]
  • [Cites] Am J Hematol. 2006 Jun;81(6):391-6 [16680753.001]
  • [Cites] J Invasive Cardiol. 2006 Jun;18(6):E173-4 [16775895.001]
  • [Cites] Clin Exp Immunol. 2006 Jul;145(1):71-80 [16792676.001]
  • [Cites] Blood. 2006 Aug 1;108(3):922-7 [16861345.001]
  • [Cites] Br J Haematol. 1982 Jul;51(3):445-50 [7104228.001]
  • [Cites] Arch Neurol. 1983 Sep;40(9):552-4 [6615286.001]
  • [Cites] J Pediatr. 1983 Dec;103(6):877-81 [6644422.001]
  • [Cites] Am J Hematol. 1983 Dec;15(4):381-90 [6606357.001]
  • [Cites] J Infect. 1984 May;8(3):274-6 [6736670.001]
  • [Cites] N Engl J Med. 1984 Sep 6;311(10):635-9 [6540841.001]
  • [Cites] Blood. 1985 Mar;65(3):584-8 [4038614.001]
  • [Cites] Ann Intern Med. 1986 Jan;104(1):47-50 [3000249.001]
  • [Cites] J Thromb Haemost. 2007 Jul;5(7):1538-44 [17470198.001]
  • [Cites] N Engl J Med. 2007 Aug 9;357(6):580-7 [17687133.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2924-30 [17548576.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):419-26 [17934346.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):511-4 [17934360.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):557-73 [17934365.001]
  • [Cites] Blood. 2007 Dec 1;110(12):3833-41 [17652264.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2227-36 [18046027.001]
  • [Cites] Thyroid. 2007 Nov;17(11):1137-42 [17887931.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4 Suppl 5):S24-34 [18096469.001]
  • [Cites] Eur J Haematol Suppl. 2008 Feb;(69):3-8 [18211567.001]
  • [Cites] Blood. 2008 Feb 1;111(3):981-6 [18223171.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):257-66 [18256550.001]
  • [Cites] Leuk Res. 2008 May;32(5):823-7 [17915315.001]
  • [Cites] Respirology. 2008 Mar;13 Suppl 1:S10-3 [18366521.001]
  • [Cites] Virol J. 2008;5:47 [18371229.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):231-7 [18628092.001]
  • [Cites] J Clin Invest. 2008 Aug;118(8):2939-49 [18654664.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1147-50 [18375792.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1078-84 [18519809.001]
  • [Cites] Hematology. 2008 Jun;13(3):181-2 [18702877.001]
  • [Cites] J Thromb Haemost. 2008 Aug;6(8):1304-12 [18489711.001]
  • [Cites] Circulation. 1997 Mar 4;95(5):1242-6 [9054855.001]
  • [Cites] Blood. 2000 Feb 1;95(3):769-75 [10648384.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):397-404 [10674912.001]
  • [Cites] Semin Hematol. 2000 Jul;37(3):239-48 [10942218.001]
  • [Cites] Stem Cells. 1996;14 Suppl 1:188-93 [11012220.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1404-6 [11100362.001]
  • [Cites] Can J Gastroenterol. 2000 Nov;14 Suppl D:60D-66D [11110614.001]
  • [Cites] Curr Gastroenterol Rep. 2001 Feb;3(1):71-8 [11177698.001]
  • [Cites] N Engl J Med. 2001 Apr 26;344(17):1286-92 [11320387.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):590-5 [11380442.001]
  • [Cites] Br J Haematol. 1986 Jul;63(3):509-16 [3089270.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] N Engl J Med. 1987 Mar 5;316(10):581-9 [3807952.001]
  • [Cites] J Clin Invest. 1987 Jul;80(1):33-40 [3597777.001]
  • [Cites] Br J Haematol. 1987 Jun;66(2):251-6 [3606961.001]
  • [Cites] Br J Haematol. 1987 Jul;66(3):337-40 [3620353.001]
  • [Cites] Eur J Haematol. 1988 May;40(5):437-41 [3378597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(24):9763-7 [3200854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5595-9 [2748605.001]
  • [Cites] Am J Pathol. 1989 Jun;134(6):1295-303 [2757119.001]
  • [Cites] J Rheumatol. 1989 Oct;16(10):1359-61 [2810261.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Feb;70(2):491-6 [2298861.001]
  • [Cites] Nature. 1990 Mar 29;344(6265):444-7 [2320112.001]
  • [Cites] Blood. 1990 May 15;75(10):1920-3 [2337668.001]
  • [Cites] Blood. 1991 Feb 1;77(3):481-5 [1991165.001]
  • [Cites] Blood. 1991 Jun 15;77(12):2668-76 [1710517.001]
  • [Cites] Arthritis Rheum. 2006 Aug;54(8):2558-67 [16868978.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Eur J Haematol. 2006 Dec;77(6):513-7 [17042765.001]
  • [Cites] J Thromb Haemost. 2007 Feb;5(2):369-77 [17096706.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1024-32 [8111044.001]
  • [Cites] J Lab Clin Med. 1994 Mar;123(3):415-20 [8133154.001]
  • [Cites] J Gastroenterol Hepatol. 1994 Jan-Feb;9(1):99-104 [8155875.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Thromb Haemost. 1994 May;71(5):571-5 [8091382.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):232-6 [7957808.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4203-8 [7994034.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):187-8 [7858499.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1252-4 [11493478.001]
  • [Cites] Circulation. 2001 Aug 21;104(8):870-5 [11514371.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1760-4 [11535509.001]
  • [Cites] Cell. 2001 Sep 7;106(5):551-61 [11551503.001]
  • [Cites] Ann Intern Med. 2001 Oct 2;135(7):502-6 [11578153.001]
  • [Cites] Arch Dis Child. 2001 Mar;84(3):227-9 [11207170.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2293-300 [11588022.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2442-7 [11588041.001]
  • [Cites] Rev Clin Exp Hematol. 2001 Sep;5(3):166-200; discussion 311-2 [11703814.001]
  • [Cites] Am J Hematol. 2001 Nov;68(3):215 [11754406.001]
  • [Cites] JAMA. 2002 Jan 23-30;287(4):505-9 [11798374.001]
  • [Cites] J Rheumatol. 2002 Jan;29(1):75-83 [11824975.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):132-4 [11835350.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2054-9 [11877279.001]
  • [Cites] N Engl J Med. 2002 Mar 28;346(13):995-1008 [11919310.001]
  • [Cites] Blood. 2002 Jul 1;100(1):344-6 [12070047.001]
  • [Cites] Chest. 2002 Jul;122(1):37-42 [12114336.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1388-98 [12149222.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):2040-5 [12190174.001]
  • [Cites] Helicobacter. 2002;7 Suppl 1:17-23 [12197905.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2148-59 [12209520.001]
  • [Cites] Eur J Haematol. 2002 Nov-Dec;69(5-6):303-8 [12460235.001]
  • [Cites] Br J Clin Pharmacol. 2003 Jan;55(1):107-11 [12534647.001]
  • [Cites] Pediatr Infect Dis J. 2003 Feb;22(2):119-22 [12586974.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):574-96 [12588344.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):124-33 [12655301.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1267-76 [12774004.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1846-54 [12806618.001]
  • [Cites] Gut. 1999 Mar;44(3):336-41 [10026317.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):220-9 [10050701.001]
  • [Cites] Thromb Haemost. 1999 Mar;81(3):436-41 [10102474.001]
  • [Cites] Gut. 1999 May;44(5):754-8 [10205219.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4054-62 [15315970.001]
  • [Cites] Drug Saf. 2004;27(15):1243-52 [15588119.001]
  • [Cites] Blood. 2005 Jan 1;105(1):215-8 [15191945.001]
  • [Cites] Blood. 2005 Jan 1;105(1):131-8 [15304392.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2004 Dec;12(12):734-6 [15619340.001]
  • [Cites] Br J Haematol. 2005 Feb;128(3):366-72 [15667539.001]
  • [Cites] Chest. 2005 Feb;127(2 Suppl):53S-59S [15706031.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2443-8 [15542578.001]
  • [Cites] Am J Med. 2005 Apr;118(4):414-9 [15808140.001]
  • [Cites] Vaccine. 2005 Jun 10;23(30):3876-86 [15917108.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):818-24 [15953010.001]
  • [Cites] Am J Hematol. 2005 Jul;79(3):175-9 [15981229.001]
  • [Cites] Blood. 2005 Jul 15;106(2):572-6 [15774614.001]
  • [Cites] Platelets. 2005 Aug;16(5):307-11 [16011982.001]
  • [Cites] Hematology. 2005 Apr;10(2):101-5 [16019455.001]
  • [Cites] Eur J Haematol. 2005 Nov;75(5):417-23 [16191092.001]
  • (PMID = 19245930.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL040387-16; United States / NHLBI NIH HHS / HL / P01 HL040387; United States / NHLBI NIH HHS / HL / P01 HL040387-16
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 185
  • [Other-IDs] NLM/ NIHMS99872; NLM/ PMC2682438
  •  go-up   go-down


25. Medlicott SA, Cox H, Dupre M, Lategan J, Auer I, Hollaar G, Debru E, Conly J: Systemic illnesses unexpectedly presenting as acute appendicitis: case studies. Can J Surg; 2008 Feb;51(1):73-4
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Appendicitis / diagnosis. Leukemia, Myeloid, Acute / complications. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Acute Disease. Adult. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Candidiasis / diagnosis. Candidiasis / drug therapy. Female. Fluconazole / therapeutic use. Humans. Liver Diseases / microbiology. Middle Aged. Splenic Diseases / microbiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Appendicitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):41-5 [9760151.001]
  • [Cites] Infect Dis Clin North Am. 2000 Sep;14(3):721-39 [10987117.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:45-8 [10707778.001]
  • [Cites] Semin Diagn Pathol. 2004 May;21(2):151-63 [15807474.001]
  • (PMID = 18248709.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole
  • [Other-IDs] NLM/ PMC2386311
  •  go-up   go-down






Advertisement